AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03773068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation A
Description: Formulation A
Study NCT03773068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation B
Description: Formulation B
Study NCT03773068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C715N]-BAY 181708 stable isotope label (SIL)
Description: 0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
Study NCT04491331 — intervention group
Intervention type: PROCEDURE
Intervention: prone position
Description: Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Avacopan 30 mg twice daily orally for 52 weeks (364 days):~- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day.
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day.
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Orally or intravenously administered
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Orally or intravenously administered
Study NCT02994927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenously administered
Study NCT02994927 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenously administered
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Orally administered
Study NCT02994927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Orally administered
Study NCT04430036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: A fully human monoclonal Anti-PD-1 Antibody
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised TRPA1 agonist solution in serial dilutions
Description: TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised TRPA1 agonist solution in serial dilutions
Description: TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 5 mg
Description: OPC, Opicapone
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 25 mg
Description: OPC, Opicapone
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLC, Placebo
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide
Study NCT02169414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide
Study NCT04555057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music selected according to the patient's individual preferences.
Study NCT02011360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Carbohydrate diet
Description: Low carbohydrate diet: 15%carb; 65%fat; 20% protein
Study NCT02011360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Fat diet
Description: Low Fat diet: 65%carb; 15%fat; 20% protein
Study NCT02994524 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rerouting technique for transsphincteric perianal fistula
Study NCT03843606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diets
Description: Different diet composition
Study NCT02695368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 on
Description: The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
Study NCT02695368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 off
Description: The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
Study NCT02695368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 on or off
Description: Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
Study NCT04430036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: A fully human monoclonal Anti-PD-1 Antibody
Study NCT04430036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Alkylating antineoplastic agent
Study NCT04430036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antimetabolite antineoplastic agent
Study NCT01085695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 10 mg normal tablet
Study NCT01085695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 1 granule containing rabeprazole 10 mg
Study NCT01085695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 2 granule containing rabeprazole 10 mg
Study NCT01085695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: Type 3 granule containing rabeprazole 10 mg
Study NCT00474136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V) 18.75 mg
Description: DIC075V 18.75 mg
Study NCT00474136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V) 37.5 mg
Description: DIC075V 37.5 mg
Study NCT00474136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral diclofenac potassium 50 mg
Description: Oral diclofenac potassium 50 mg
Study NCT03544385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringers Solution
Description: Treatment vs Placebo
Study NCT03544385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: treatment vs placebo
Study NCT03928990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph accelerometer
Description: ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
Study NCT01913509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Therapy of FES and BAT
Description: FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
Study NCT01913509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
Study NCT02586116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nanOss
Description: nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
Study NCT02586116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Plus
Description: C-Plus PEEK IBF Device with autograft
Study NCT02730546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02730546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02730546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02730546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02949986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based Fall Prevention
Description: The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
Study NCT03018509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active drug tablets
Study NCT02730546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Individual dose of RHI administered subcutaneously
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Individual dose of lispro administered subcutaneously
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject
Description: Individual dose of VIAject administered subcutaneously
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject 50%
Description: Individual dose of VIAject 50% administered subcutaneously
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject/Insulin Glargine
Description: VIAject mixed wiht insulin glargine and administered subcutaneously
Study NCT01000922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine/VIAject
Description: Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
Study NCT03872830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.
Study NCT03872830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.
Study NCT02730546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02730546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02730546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02730546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT02730546 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03124914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular tests
Description: Neuromuscular tests
Study NCT02730546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo curative-intent surgery
Study NCT01644812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Study NCT01644812 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Study NCT01573611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: 36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
Study NCT01573611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
Study NCT02630355 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb
Study NCT02630355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: Inflation of blood pressure cuff in lower limb
Study NCT04056715 — intervention group
Intervention type: DEVICE
Intervention: Zio XT
Description: ambulatory cardiac monitoring device
Study NCT01406366 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group 1: Bright Futures Oral Health Curriculum
Description: Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
Study NCT01406366 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group 2: Iron Deficiency Training Module
Description: Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
Study NCT03011424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal liver support therapy (ELS)
Description: ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
Study NCT01842334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT administered to to both DCS and placebo group.
Study NCT01842334 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT administered to to both DCS and placebo group.
Study NCT01842334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: NRT administered to both DCS and placebo group.
Study NCT01842334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: NRT administered to both DCS and placebo group.
Study NCT04139603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic kinesio taping
Description: Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.
Study NCT04139603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal supported lumbopelvic kinesio taping
Description: Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.
Study NCT04139603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tapng
Description: Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided.
Study NCT02615561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)
Description: 2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
Study NCT02615561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New cosmetic Bepanthen product: Pumpkin (BAY207543)
Description: Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
Study NCT02615561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stelatopia (cosmetic comparator)
Description: Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
Study NCT02268942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD
Description: Implant of HeartWare HVAD via thoracotomy implant technique
Study NCT02268942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Thoracotomy implant technique
Study NCT02169466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone
Study NCT02169466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo
Study NCT02169466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS
Description: controlled-release levodopa 100 mg/benserazide 25 mg
Study NCT00296478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin
Description: Endometrin 100mg BID x 10weeks
Study NCT03461705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano Verrata Pressure Wire
Description: Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature.
Study NCT03461705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical (SJM) Aeris Pressure Wire System
Description: The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.